Hologic (NASDAQ:HOLX) Cut to Hold at Wall Street Zen

Key Points

• Hologic has been downgraded from a "buy" to a "hold" rating by Wall Street Zen in a recent report.
• Despite the downgrade, several analysts maintain positive views with Hologic receiving an average "Moderate Buy" rating and a price target of $78.00.
• Hologic reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year.

Hologic (NASDAQ:HOLX - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Monday.

Several other research analysts also recently issued reports on HOLX. Mizuho set a $75.00 price target on Hologic in a research note on Thursday, July 31st. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Evercore ISI lifted their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Morgan Stanley lifted their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, UBS Group lifted their price objective on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Trading Down 2.9%

NASDAQ:HOLX opened at $64.45 on Monday. The company has a market capitalization of $14.33 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic has a 52-week low of $51.90 and a 52-week high of $84.39. The stock has a fifty day simple moving average of $66.43 and a 200-day simple moving average of $62.64.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business's revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hologic

Several hedge funds and other institutional investors have recently modified their holdings of HOLX. Chung Wu Investment Group LLC acquired a new position in shares of Hologic in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 273 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Hologic in the 2nd quarter valued at about $33,000. Zions Bancorporation National Association UT acquired a new position in shares of Hologic in the 1st quarter valued at about $34,000. Finally, Cromwell Holdings LLC lifted its stake in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 436 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.